There is no doubt that a deeper understanding of the interaction between CD44 and EGFR in cancer progression will provide better approaches to cancer treatment, and that combined EGFR/CD44 targeting may be the future direction in the treatment of some types of cancer [106]. The gene discussed is EGFR; the disease is cancer.